2. Signaling Pathways
  3. Cytoskeleton
  4. Integrin
  5. α4β7 Isoform
  6. α4β7 Antagonist

α4β7 Antagonist

α4β7 Antagonists (6):

Cat. No. Product Name Effect Purity
  • HY-15770
    TR-14035
    		Antagonist 99.87%
    TR-14035 is a orally active dual α4β7/α4β1 integrin antagonist, with IC50 s of 7 nM and 87 nM for α4β7 and α4β1, respectively. TR-14035 can be used for the research of inflammation and autoimmune diseases.
  • HY-14951
    Firategrast
    		Antagonist 99.75%
    Firategrast (SB 683699) is an orally active and specific α4β1/α4β7 integrin antagonist. Firategrast reduces trafficking of lymphocytes into the central nervous system (CNS) and decreases multiple sclerosis (MS) activity.
  • HY-177080
    Emvistegrast
    		Antagonist 98.06%
    Emvistegrast (GS-1427) is a quinolone derivative. Emvistegrast is also an inhibitor of α4β7 integrin. Emvistegrast can be used to investigate diseases mediated by α4β7 integrin, such as inflammatory bowel disease.
  • HY-138542
    RO0270608
    		Antagonist 98.80%
    RO0270608, the active metabolite of R411, is a dual alpha4beta1-alpha4beta7 (α4β1/α4β7) integrin antagonist. Antiinflammatory activity.
  • HY-114225
    TBC-4746
    		Antagonist
    TBC-4746 is a α4β1/α4β7 integrin antagonist. TBC-4746 can be used in the research of asthma and multiple sclerosis.
  • HY-14189
    Valategrast hydrochloride
    		Antagonist
    Valategrast hydrochloride (R-411) is a potent integrin α4β1 (VLA-4) and α4β7 dual antagonist. Valategrast hydrochloride has the potential for Chronic obstructive pulmonary disease (COPD) and asthma treatment.